Related Experiment Video
Updated: Jul 21, 2025
Analysis of Group IV Viral SSHHPS Using In Vitro and In Silico Methods
Published on: December 21, 2019
Identification of a Putative SARS-CoV-2 Main Protease Inhibitor through In Silico Screening of Self-Designed
Nanxin Liu1, Zeyu Yang1, Yuying Liu1
1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China.
Abstract:
There have been outbreaks of SARS-CoV-2 around the world for over three years, and its variants continue to evolve. This has become a major global health threat. The main protease (Mpro, also called 3CLpro) plays a key role in viral replication and proliferation, making it an attractive drug target. Here, we have identified a novel potential inhibitor of Mpro, by applying the virtual screening of hundreds of nilotinib-structure-like compounds that we designed and synthesized. The screened compounds were assessed using SP docking, XP docking, MM-GBSA analysis, IFD docking, MD simulation, ADME/T prediction, and then an enzymatic assay in vitro. We finally identified the compound V291 as a potential SARS-CoV-2 Mpro inhibitor, with a high docking affinity and enzyme inhibitory activity. Moreover, the docking results indicate that His41 is a favorable amino acid for pi-pi interactions, while Glu166 can participate in salt-bridge formation with the protonated primary or secondary amines in the screened molecules. Thus, the compounds reported here are capable of engaging the key amino acids His41 and Glu166 in ligand-receptor interactions. A pharmacophore analysis further validates this assertion.
Insights
Researchers identified V291, a novel compound targeting the SARS-CoV-2 main protease (Mpro), crucial for viral replication. This discovery offers a potential new therapeutic strategy against evolving COVID-19 variants.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- SARS-CoV-2 variants pose an ongoing global health threat.
- The main protease (Mpro) is essential for viral replication and a key drug target.
Purpose of the Study:
- To identify novel inhibitors of SARS-CoV-2 Mpro.
- To design and synthesize nilotinib-structure-like compounds for virtual screening.
Main Methods:
- Virtual screening including SP docking, XP docking, MM-GBSA, IFD docking, and MD simulation.
- ADME/T prediction and in vitro enzymatic assays.
- Pharmacophore analysis to understand ligand-receptor interactions.
Main Results:
- Compound V291 demonstrated high docking affinity and significant in vitro enzyme inhibitory activity against SARS-CoV-2 Mpro.
- Docking results revealed favorable interactions with key amino acids His41 and Glu166.
- The identified compounds effectively engage His41 via pi-pi interactions and Glu166 via salt-bridge formation.
Conclusions:
- Compound V291 is a promising potential inhibitor of SARS-CoV-2 Mpro.
- The study provides insights into the molecular interactions critical for Mpro inhibition.
- This research contributes to the development of new antiviral therapies against SARS-CoV-2.
